Home » Semiconductors, Small Caps, and Biotech’s In Focus

Semiconductors, Small Caps, and Biotech’s In Focus

Subscribe to The Free Market Chronicle and join the 2,750 subscribers getting it for FREE!

[widget id=”text-28″]

[widget id=”text-23″]

Semiconductors, Small Caps, and Biotech’s In Focus

[widget id=”text-19″]

Semiconductor stocks were the weakest group today, with the SOXX ETF dropping by roughly 1.5 percent. The big loser in the group was Applied Materials (AMAT), dropping by about 7 percent. The company reported slightly lower than expected revenue guidance for next quarter. But let’s face it does it come as a surprise? It shouldn’t at this point. Many of the biggest chipmakers have disappointed, going all the way to the first significant report out of Taiwan Semi back in the middle of April. AMAT noted smartphone sales have been weak, and below expectations. Well, there is a shocker! Haven’t we heard that one before?

Despite the pullback, the group is on fire in the month, rising by nearly 7 percent even after today. So, you can’t complain too much, and the outlook for the group still looks solid on many fronts.


Can you believe AMD shares are up nearly 40 percent just since the start of April? Wow. That relative strength index is well into overbought levels, with a reading of around 73. But this one could be overdue for a modest pullback back to $12.50ish.


[widget id=”text-22″]

Small Caps

Despite the S&P 500 stalling out, the Russell 2000 continues to reach new record highs, and the breakout continues.

russell 2000

[widget id=”text-23″]


With stocks like GrubHub in the index, it would seem there are more gains likely to be had. The chart on GrubHub looks powerful and ready to breakout.


Proofpoint is another example:


[widget id=”wordads_sidebar_widget-41″]


Well, Biotech stocks as measured by the XBI, are up over 5 percent just since May 10, maybe it has something to do with the speech last week on drug prices? I’m not sure about that; I’m looking through some of the big movers, like Loxo Oncology, popping over 30 percent after positive phase 1 data presentation at ASCO.
XBI Chart

XBI data by YCharts

We will see what the next week or so brings, and which stocks continue to perform the best in the group. The leadership in that sector is still not coming for the most part from the big players.

Overall it was a solid week in which to build for the broader market, and I will discuss more in further detail over the weekend

That’s it!


Photo credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

#smallcaps #semiconductors #biotech #proofpoint #grubhub #amd